There are 3161 resources available
1306P - Trametinib plus anlotinib in non-G12C KRAS-mutant non-small cell lung cancer: A single-center, open-label, single-cohort study
Presenter: Baohui Han
Session: Poster session 05
Resources:
Abstract
1308P - Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations
Presenter: Lea Ruge
Session: Poster session 05
1309P - A genomic scar based signature (HRDsig) and biallelic BRCA alterations identify a homologous recombination deficiency (HRD) phenotype of non-small cell lung cancer (NSCLC) potentially actionable to the PARP inhibitor rucaparib: Post-hoc analysis of lung-MAP substudy S1900A
Presenter: Jonathan Riess
Session: Poster session 05
1310P - SHR-A1921: A trophoblast cell-surface antigen 2 (TROP-2) targeted antibody-drug conjugate (ADC) for the treatment of advanced NSCLC
Presenter: Jie Wang
Session: Poster session 05
1311P - Phase II, open-label study of frontline tusamitamab ravtansine with pembrolizumab ± chemotherapy in advanced non-squamous non-small cell lung cancer: Updated results from CARMEN-LC05 trial
Presenter: Delvys Rodriguez Abreu
Session: Poster session 05
1312P - Datopotamab deruxtecan (Dato-DXd) vs docetaxel (DTX) in patients (pts) with advanced nonsquamous (NSQ) non-small cell lung cancer (NSCLC) with brain metastases (mets): Results from TROPION-Lung01
Presenter: Elvire Pons-Tostivint
Session: Poster session 05
1314P - Patient-reported outcomes (PROs) from the phase III EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel (doc) in metastatic non-small cell lung cancer (mNSCLC)
Presenter: Niels Reinmuth
Session: Poster session 05
1315P - BC3195, a novel ADC targeting CDH3: Preliminary results of a first-in human phase I study in patients with advanced solid malignancies
Presenter: Hua-Jen Chen
Session: Poster session 05